1. Home
  2. PLSE vs AUPH Comparison

PLSE vs AUPH Comparison

Compare PLSE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$19.15

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.72

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSE
AUPH
Founded
2014
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.9B
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
PLSE
AUPH
Price
$19.15
$15.72
Analyst Decision
Buy
Buy
Analyst Count
1
4
Target Price
$22.00
$17.25
AVG Volume (30 Days)
235.0K
1.1M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5075.00
EPS
N/A
2.07
Revenue
N/A
$283,055,000.00
Revenue This Year
$840.00
$16.53
Revenue Next Year
$287.54
$16.24
P/E Ratio
N/A
$7.73
Revenue Growth
N/A
20.38
52 Week Low
$12.56
$6.83
52 Week High
$26.30
$16.54

Technical Indicators

Market Signals
Indicator
PLSE
AUPH
Relative Strength Index (RSI) 43.99 63.32
Support Level $13.75 $14.56
Resistance Level $20.40 $16.28
Average True Range (ATR) 1.55 0.56
MACD -0.13 0.20
Stochastic Oscillator 18.85 79.04

Price Performance

Historical Comparison
PLSE
AUPH

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: